Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19942536 | 0.79 | CHRNB2 (0.36) | MTNR1AMTNR1BCHRNB2CHRNA4CHRNA7 | |
| SCHEMBL22606460 | 0.76 | CHRNB2 (0.34) | SMN1; SMN2EPHX1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL24782517 | 0.72 | CHRNB2 (0.32) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL16840695 | 0.70 | — | — | |
| SCHEMBL16840697 | 0.70 | — | — | |
| SCHEMBL16840701 | 0.70 | — | — | |
| SCHEMBL16840698 | 0.70 | — | — | |
| SCHEMBL24754202 | 0.70 | — | — | |
| SCHEMBL16840696 | 0.70 | — | — | |
| SCHEMBL23570405 | 0.69 | POLB (0.31) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3290418-B1 | JANUS KINASE (JAK) INHIBITORS | WUXI FORTUNE PHARMACEUTICAL CO LTD (CN) | 2019-05-15 | — | — | EP | disclosed |
| US-10174036-B2 | Substituted pyrazoles as JAK inhibitors | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2019-01-08 | — | — | US | disclosed |
| US-20180179209-A1 | JAK INHIBITORS | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2018-06-28 | — | — | US | disclosed |
| EP-3290418-A1 | JAK INHIBITORS | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2018-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174036-B2 | Substituted pyrazoles as JAK inhibitors | JAK1, JAK2, JAK3 | ALDH1A1 1465/4885POLB 3160/4885SMN1; SMN2 4476/4885 |
| US-20180179209-A1 | JAK INHIBITORS | JAK2, JAK1, JAK3 | ALDH1A1 3018/4885POLB 2663/4885SMN1; SMN2 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.